Le Gall, F.; Kipriyanov, SM; Moldenhauer, G; Little, M (1999). “Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding”. FEBS Letters453 (1): 164–168. doi:10.1016/S0014-5793(99)00713-9. PMID10403395.
Dincq, S; Bosman, F; Buyse, MA; Degrieck, R; Celis, L; De Boer, M; Van Doorsselaere, V; Sablon, E (2001). “Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway”. Protein Expression and Purification22 (1): 11–24. doi:10.1006/prep.2001.1417. PMID11388794.
Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). “Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery”. Stroke: A Journal of Cerebral Circulation35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID15331798.
Le Gall, F.; Kipriyanov, SM; Moldenhauer, G; Little, M (1999). “Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding”. FEBS Letters453 (1): 164–168. doi:10.1016/S0014-5793(99)00713-9. PMID10403395.
Dincq, S; Bosman, F; Buyse, MA; Degrieck, R; Celis, L; De Boer, M; Van Doorsselaere, V; Sablon, E (2001). “Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway”. Protein Expression and Purification22 (1): 11–24. doi:10.1006/prep.2001.1417. PMID11388794.
Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). “Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery”. Stroke: A Journal of Cerebral Circulation35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID15331798.